Product Detail
Biperiden Hydrochloride
Biperiden Hydrochloride API
Stock Status: In Stock
Login to view price
Live
For Research & Analytical Purposes. Not for Personal use.
Category
API
API Family
Biperiden Hydrochloride
Storage
Store at refrigerator (2-8°C) for long term storage
Hazard Information
Refer MSDS for accurate information.
Biperiden Hydrochloride Product Information
Biperiden Hydrochloride is listed under API. It is associated with Biperiden Hydrochloride and is intended for analytical research, quality control and pharmaceutical reference standard applications. The product is supplied by Clearsynth under CAT No. CS-T-49157.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
Biperiden Hydrochloride
CAS No.
1235-82-1
CAT No.
CS-T-49157
Molecular Formula
C₂₁H₃₀ClNO
Molecular Weight
347.92
Category
API Family
Storage Condition
Store at refrigerator (2-8°C) for long term storage
SMILES
OC(C1=CC=CC=C1)(C2C(C3)C=CC3C2)CCN4CCCCC4.[H]Cl
IUPAC Name
1-(5-bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol;hydrochloride
Purity by HPLC
Not less than 95 %
Hazard Compound
Refer MSDS for accurate information.
Description
Overview
"Biperiden hydrochloride is antiparkinsonian; non-selective muscarinic receptor antagonist. Biperiden is used for the adjunctive treatment of all forms of Parkinson's Disease (postencephalitic, idiopathic, and arteriosclerotic); also commonly used to improve parkinsonian signs and symptoms related to antipsychotic drug therapy. "
Synonyms
1-Piperidinepropanol, α-bicyclo[2.2.1]hept-5-en-2-yl-α-phenyl-,hydrochloride
Application Notes
"Biperiden hydrochloride is antiparkinsonian; non-selective muscarinic receptor antagonist. Biperiden is used for the adjunctive treatment of all forms of Parkinson's Disease (postencephalitic, idiopathic, and arteriosclerotic); also commonly used to improve parkinsonian signs and symptoms related to antipsychotic drug therapy. "
References
"Patela, Y,, et al,: Talanta, 47, 625 (1998), Bebawy, L,, et al: J, Pharm, Biomed, Anal,, 20, 663 (1999), Dinc, E,, et al,: J, Pharm, Biomed, Anal,, 28, 591 (2002), "
